Author Archives: Margarida Azevedo, MSc

Pharnext’s PXT3003 Granted Priority Review in China for Charcot-Marie-Tooth Type 1A

The French biopharmaceutical company Pharnext recently announced that its candidate for the treatment of Charcot-Marie-Tooth disease type 1A (CMT1A) was granted priority review by the China Food and Drug Administration (CFDA). PXT3003 is a fixed-dose combination of baclofen, naltrexone, and sorbitol. The therapy candidate has received orphan drug status in both…